Melanoma: Survival Has Risen from 44 to 77 Percent
Published
New research findings show that the treatment of melanoma (skin cancer of moles) has improved considerably in recent years. According to the report, the proportion of patients who survive has increased from 44 to 77 percent. The researchers point to new medicines and treatment methods as an important reason for this development.
There are nevertheless exceptions. When it comes to uveal melanoma, meaning melanoma in the eye, the researchers find no sign that immunotherapy has improved survival. Immunotherapy is a treatment that uses the body's own immune system to fight cancer cells. For this type of cancer, the situation remains difficult.
The median survival for uveal melanoma is around one year, regardless of which treatment the patient receives. Median survival means that half of the patients live longer than this, and half die earlier. The figure shows that there is still a need for new research on this rare form of cancer.
Overall, the results are positive for many patients with melanoma. At the same time, the findings on uveal melanoma show that progress is not equal for all types of cancer. The researchers stress that further investigations are needed to find better treatments for patients with uveal melanoma.
Sources: HealthTalk
More Norway news
- Cybersecurity has become a leadership responsibility
- Former soldier has built challenger to OBOS
- More Customers Don't Necessarily Mean Better Profitability
- New Norway chief at Advania
- Professor Moumita Sen researches religion, politics and power
- Conference in Oslo to examine how Norwegian life sciences can reach their potential
- From Emissions to Resource: Can CO₂ Be Used in New Industry?
- Norway heard in the EU's new Arctic strategy